Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could fermented foods tame metabolic syndrome?

NCT ID NCT06587958

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating fermented plant-based foods (like certain vegetables and grains) can improve health in people with metabolic syndrome—a condition that raises risk for heart disease and diabetes. About 89 adults with signs of metabolic syndrome ate either fermented plant foods, non-fermented plant foods, or their usual diet for six weeks each. Researchers measured inflammation, blood sugar, and other risk factors to see if the fermented foods made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fermented plant-based foods
What this could lead to
If it works, this could point toward a simple dietary approach to help manage metabolic syndrome and reduce inflammation.
What could go wrong
This is a small, completed trial with only 89 participants. The results may not apply to everyone, and dietary changes can be hard to stick with long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

89 people

The number who actually took part.

Started

Oct 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sign of metabolic syndrome Waist circumference \> 102 cm/88 cm M/W and at least one of the following: * High density lipoprotein (HDL) ≤1.0 mmol/L men / HDL ≤1.3 mmol/L * Triglycerides ≥ 1,7 mmol/L * Blood pressure ≥130/85 mmHg * Fasting glucose ≥5.6 mmol/L Other inclusion criteria: * Signed informed consent * Willingness to consume the intervention foods * Body mass index 25-35 kg/m2 * Hemoglobin 120-160 g/L * Serum thyroid-stimulating hormone (S-TSH) \<4 mIU/L * Serum C-reactive protein (S-CRP) \<5 mg/L * Access to a -18⁰ C freezer * Any medication stable for the last 14 days. Exclusion Criteria: * Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study. * Following any weight reduction program or having followed one during the last 6 months * Food allergies or intolerances * History of stomach or gastrointestinal conditions (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, Helicobacter infection, Peptic ulcer disease, untreated celiac disease, etc.) * Previous major gastrointestinal surgery * Pregnant or lactating or wish to become pregnant during the period of the study. * Unable to understand written and spoken Swedish * Lack of suitability for participation in the trial, for any reason, as judged by the medical doctor or PI. * Pharmacological medication with drugs known to affect the microbiota, e.g., antibiotics, within 6 months prior to baseline. * Intake of any probiotic pills or foods enriched in probiotics within 6 months prior to baseline. * Type I diabetes * Small bowel bacterial overgrowth * Diarrheal disease * Receiving pharmacological treatment for type II diabetes (treatments based on lifestyle interventions are acceptable, as long as it is compatible with the study protocol) * Using nicotine products on a daily basis (including chewing gum, patches, snus etc.) * History of heart failure or heart attack (TIA) within 1 year prior to screening * Thyroid disorder * Planned surgery within the next eight months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic cardiovascular syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sahlgrenska University Hospital, Wallenberg Lab

    Gothenburg, Ästra Götaland, 41346, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.